Posted by Michael Wonder on 02 Jul 2018
Acadia Pharmaceuticals announces FDA approval of new dosing formulation and strength for Nuplazid (pimavanserin)
29 June 2018 - New dosing formulation and strength address needs in treating patients with hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia Pharmaceuticals today announced FDA approval of a new capsule dose formulation and a new tablet strength of Nuplazid (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with Parkinson’s disease psychosis.
The FDA approval of a 34 mg Nuplazid capsule formulation will provide patients with the recommended 34 mg once daily dose in a single, small capsule, reducing patient pill burden versus the current administration of two 17 mg tablets. In addition, the FDA approval of a 10 mg tablet provides an optimised lower dosage strength in those patients who are concomitantly receiving strong cytochrome 3A4 inhibitors which can inhibit the metabolism of Nuplazid.
